These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1320532)

  • 1. Medical therapy in spinal muscular atrophy: a realistic expectation?
    Jennekens FG
    Clin Neurol Neurosurg; 1992; 94 Suppl():S89-92. PubMed ID: 1320532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Modern principles of therapy for patients with spinal muscular atrophy].
    Bofanova NS; Eliseeva AR; Onchina VS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(3):34-40. PubMed ID: 36946394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stem cell-derived neurotrophic support for the neuromuscular junction in spinal muscular atrophy.
    Wyatt TJ; Keirstead HS
    Expert Opin Biol Ther; 2010 Nov; 10(11):1587-94. PubMed ID: 20955113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of thyrotropin-releasing hormone in the treatment of spinal muscular atrophy.
    Takeuchi Y; Miyanomae Y; Komatsu H; Oomizono Y; Nishimura A; Okano S; Nishiki T; Sawada T
    J Child Neurol; 1994 Jul; 9(3):287-9. PubMed ID: 7930408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy.
    Lee BH; Waldrop MA; Connolly AM; Ciafaloni E
    Muscle Nerve; 2021 Aug; 64(2):153-155. PubMed ID: 33959970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nerve growth factors: a hypothesis on their role in the pathogenesis of infantile spinal amyotrophies].
    Henderson CE; Fardeau M
    Rev Neurol (Paris); 1988; 144(11):730-6. PubMed ID: 3231962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spinal muscular atrophy: state of the art and new therapeutic strategies.
    Messina S; Sframeli M; Maggi L; D'Amico A; Bruno C; Comi G; Mercuri E
    Neurol Sci; 2022 Dec; 43(Suppl 2):615-624. PubMed ID: 33871750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog.
    Ohuchi K; Funato M; Kato Z; Seki J; Kawase C; Tamai Y; Ono Y; Nagahara Y; Noda Y; Kameyama T; Ando S; Tsuruma K; Shimazawa M; Hara H; Kaneko H
    Stem Cells Transl Med; 2016 Feb; 5(2):152-63. PubMed ID: 26683872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrophysiological findings in childhood spinal muscular atrophies.
    Hausmanowa-Petrusewicz I
    Rev Neurol (Paris); 1988; 144(11):716-20. PubMed ID: 3231960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor nerve conduction studies on children with spinal muscular atrophy.
    Miyanomae Y; Takeuchi Y; Nishimura A; Kawase S; Hirai K; Ochi M; Sawada T
    Acta Paediatr Jpn; 1996 Dec; 38(6):576-9. PubMed ID: 9002289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loganin possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt/mTOR in experimental models of spinal muscular atrophy.
    Tseng YT; Chen CS; Jong YJ; Chang FR; Lo YC
    Pharmacol Res; 2016 Sep; 111():58-75. PubMed ID: 27241020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Degeneration of cocultures of spinal muscular atrophy muscle cells and rat spinal cord explants is not due to secreted factors and cannot be prevented by neurotrophins.
    Braun S; Croizat B; Lagrange MC; Poindron P; Warter JM
    Muscle Nerve; 1997 Aug; 20(8):953-60. PubMed ID: 9236785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infantile spinal progressive muscular atrophy in twins.
    POIRIER R; CORBET RC; BUCKWOLD AE
    Can Med Assoc J; 1951 Oct; 65(4):342-3. PubMed ID: 14879299
    [No Abstract]   [Full Text] [Related]  

  • 14. Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy.
    Dachs E; Piedrafita L; Hereu M; Esquerda JE; Calderó J
    Neuroscience; 2013 Oct; 250():417-33. PubMed ID: 23876328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals.
    Hahnen E; Forkert R; Marke C; Rudnik-Schöneborn S; Schönling J; Zerres K; Wirth B
    Hum Mol Genet; 1995 Oct; 4(10):1927-33. PubMed ID: 8595417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing a standardized therapeutic testing protocol for spinal muscular atrophy.
    Tsai LK; Tsai MS; Lin TB; Hwu WL; Li H
    Neurobiol Dis; 2006 Nov; 24(2):286-95. PubMed ID: 16952456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurodegenerative changes are prevented by Erythropoietin in the pmn model of motoneuron degeneration.
    Ruiz M; Martínez-Vidal AF; Morales JM; Monleón D; Giménez Y Ribotta M
    Neuropharmacology; 2014 Aug; 83():137-53. PubMed ID: 24769002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening.
    Weng WC; Hsu YK; Chang FM; Lin CY; Hwu WL; Lee WT; Lee NC; Chien YH
    Genet Med; 2021 Feb; 23(2):415-420. PubMed ID: 33033402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Infantile spinal muscular atrophy : therapeutic (R)evolution].
    Daron A; Delstanche S; Dangouloff T; Servais L
    Rev Med Liege; 2019 Feb; 74(2):82-85. PubMed ID: 30793560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model.
    Ando S; Funato M; Ohuchi K; Kameyama T; Inagaki S; Seki J; Kawase C; Tsuruma K; Shimazawa M; Kaneko H; Hara H
    Eur J Pharmacol; 2017 Nov; 814():161-168. PubMed ID: 28826912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.